Prices delayed by at least 15 minutes | Print


BIOMERIEUX (BIM)

BIOMERIEUX
Sell: €99.9|Buy: €101.8|Change: 2.30 (-2.25%)

Open 

€102.1


Previous close 

€102.3


Trade high 

€102.1


Volume 

147,236


Year high 

€108.90


Year low 

€84.54


Dividend yield 

0.85%


Market capitalisation 

€11.82 bn


P/E ratio 

33.22


ISIN 

FR0013280286


This share can be held in a Dealing accountISALifetime ISAJISASIPP

Share price

Performance 30/04/2024

1D | 1M | 3M | 1Y | 3Y ann | 5Y ann | 10Y ann


Total return (%)
BIOMERIEUX- 2.25
More...

Company profile

BioMerieux designs, develops, and manufactures a broad portfolio of in vitro diagnostics for detecting disease-causing pathogens and contamination. The company operates in four segments: molecular biology (38% of 2021 sales), microbiology (31%), immunoassays (14%), and industrial applications (about 17%). The Americas account for the largest portion of the firm's revenue (49%), followed by Europe, the Middle East, and Africa (33%), and Asia-Pacific (18%). BioMerieux is headquartered in Marcy-l'Etoile, France.

Sector 

Healthcare


AJ Bell Management Limited (company number 03948391), AJ Bell Securities Limited (company number 02723420) and AJ Bell Asset Management Limited (company number 09742568) are authorised and regulated by the Financial Conduct Authority. All companies are registered in England and Wales at 4 Exchange Quay, Salford Quays, Manchester M5 3EE. See website for full details. AJ Bell procures the provision of the Morningstar Licensed Tools on an “as is” basis and does not guarantee the performance of or accept liability for the Licensed Tools. To the maximum extent permitted by law, AJ Bell excludes liability for the Licensed Tools, including liability for any failure, interruption, delay or defect in the performance of any Licensed Tool, unless it arises as a direct result of the negligence of AJ Bell.

© Copyright 2024 AJ Bell. All rights reserved.